Table 1. Patient characteristics and covariate balance before and after propensity matching.
| After Propensity Matching | Before Propensity Matching | |||||
|---|---|---|---|---|---|---|
| BEB Treatment Cohort | Untreated Control Cohort | SMD | BEB Treatment Cohort | Untreated Control Cohort | SMD | |
| N = 1,091 | N = 1,091 | N = 1,099 | N = 18,679 | |||
| Age | 64.0 [50.0,74.0] | 64.0 [50.0,74.0] | 64.0 [50.0,74.0] | 46.0 [32.0,63.0] | ||
| Age Groups | ||||||
| 18–35 | 82 (7.5) | 82 (7.5) | 0.00 | 83 (7.6) | 5,969 (32.0) | -0.92 |
| 35–50 | 200 (18.3) | 200 (18.3) | 0.00 | 202 (18.4) | 4,568 (24.5) | 0.16 |
| 50–60 | 168 (15.4) | 168 (15.4) | 0.00 | 169 (15.4) | 2,849 (15.3) | 0.00 |
| 60–70 | 275 (25.2) | 275 (25.2) | 0.00 | 275 (25.0) | 2,539 (13.6) | 0.26 |
| >70 | 366 (33.5) | 366 (33.5) | 0.00 | 370 (33.7) | 2,754 (14.7) | 0.40 |
| Sex | ||||||
| Male | 469 (43.0) | 474 (43.4) | -0.01 | 474 (43.1) | 7,366 (39.4) | 0.07 |
| Fully Vaccinated | ||||||
| Yes | 748 (68.6) | 748 (68.6) | 0.00 | 752 (68.4) | 7,430 (39.8) | 0.62 |
| No | 298 (27.3) | 298 (27.3) | 0.00 | 301 (27.4) | 5,538 (29.6) | -0.05 |
| Unknown | 45 (4.1) | 45 (4.1) | 0.00 | 46 (4.2) | 5,711 (30.6) | -1.32 |
| Race/Ethnicity | ||||||
| White | 859 (78.7) | 866 (79.4) | -0.02 | 867 (78.9) | 11,801 (63.2) | 0.39 |
| Black | 48 (4.4) | 44 (4.0) | 0.02 | 48 (4.4) | 1,058 (5.7) | -0.06 |
| Hispanic | 120 (11.0) | 109 (10.0) | 0.03 | 120 (10.9) | 3,542 (19.0) | -0.26 |
| Asian/Pacific Islander | 13 (1.2) | 16 (1.5) | -0.03 | 13 (1.2) | 360 (1.9) | -0.07 |
| Native American/Alaskan | 8 (0.7) | 9 (0.8) | -0.01 | 8 (0.7) | 228 (1.2) | -0.06 |
| Unknown | 43 (3.9) | 47 (4.3) | -0.02 | 43 (3.9) | 1,690 (9.0) | -0.26 |
| BMI Group | ||||||
| ≤20 | 24 (2.2) | 24 (2.2) | 0.00 | 26 (2.4) | 811 (4.3) | -0.13 |
| 20–25 | 164 (15.0) | 164 (15.0) | 0.00 | 166 (15.1) | 4,005 (21.4) | -0.18 |
| 25–30 | 305 (28.0) | 305 (28.0) | 0.00 | 307 (27.9) | 4,968 (26.6) | 0.03 |
| 30–35 | 236 (21.6) | 236 (21.6) | 0.00 | 236 (21.5) | 3,477 (18.6) | 0.07 |
| 35–40 | 160 (14.7) | 160 (14.7) | 0.00 | 161 (14.6) | 1,844 (9.9) | 0.14 |
| >40 | 137 (12.6) | 137 (12.6) | 0.00 | 137 (12.5) | 1,545 (8.3) | 0.13 |
| Unknown | 165 (6.0) | 65 (6.0) | 0.00 | 66 (6.0) | 2,029 (10.9) | -0.20 |
| Time period | ||||||
| 4/05-30/2022 | 103 (9.4) | 131 (12.0) | -0.09 | 103 (9.4) | 1,213 (6.5) | 0.10 |
| 5/01-31/2022 | 249 (22.8) | 268 (24.6) | 0.00 | 252 (22.9) | 3,652 (19.6) | 0.08 |
| 6/01-30/2022 | 372 (34.1) | 358 (32.8) | 0.04 | 375 (34.1) | 6,746 (36.1) | -0.04 |
| 7/01-31/2022 | 367 (33.6) | 334 (30.6) | 0.03 | 369 (33.6) | 7,040 (37.7) | -0.09 |
| 8/01/2022 | 0 (0.0) | 0 (0.0) | 0.00 | 0 (0.0) | 28 (0.1) | -0.04 |
| Myocardial Infarction | 64 (5.9) | 47 (4.3) | 0.06 | 65 (5.9) | 526 (2.8) | 0.13 |
| Heart Failure | 91 (8.3) | 73 (6.7) | 0.06 | 93 (8.5) | 797 (4.3) | 0.15 |
| Cerebrovascular Disease | 93 (8.5) | 66 (6.0) | 0.09 | 94 (8.6) | 674 (3.6) | 0.18 |
| Hemiplegia or Paraplegia | 12 (1.1) | 11 (1.0) | 0.01 | 12 (1.1) | 161 (0.9) | 0.02 |
| Peripheral Vascular Disease | 100 (9.2) | 84 (7.7) | 0.05 | 101 (9.2) | 725 (3.9) | 0.18 |
| Chronic Pulmonary Disease | 343 (31.4) | 311 (28.5) | 0.06 | 346 (31.5) | 3,907 (20.9) | 0.23 |
| Dementia | 21 (1.9) | 19 (1.7) | 0.01 | 21 (1.9) | 237 (1.3) | 0.05 |
| Hypertension | 573 (52.5) | 534 (48.9) | 0.07 | 580 (52.8) | 5,199 (27.8) | 0.50 |
| Diabetes without Chronic Complications | 242 (22.2) | 242 (22.2) | 0.00 | 246 (22.4) | 2,236 (12.0) | 0.25 |
| Diabetes with Chronic Complications | 104 (9.5) | 104 (9.5) | 0.00 | 110 (10.0) | 838 (4.5) | 0.18 |
| Renal Mild-Moderate-Advanced Disease (CKD stage 1–4) | 147 (13.5) | 118 (10.8) | 0.08 | 153 (13.9) | 780 (4.2) | 0.28 |
| Renal Severe Disease (CKD stage 5 and ESRD) | 37 (3.4) | 21 (1.9) | 0.08 | 39 (3.5) | 201 (1.1) | 0.13 |
| Mild Liver Disease | 117 (10.7) | 95 (8.7) | 0.07 | 117 (10.6) | 1,034 (5.5) | 0.17 |
| Moderate to Severe Liver Disease | 34 (3.1) | 18 (1.6) | 0.08 | 35 (3.2) | 185 (1.0) | 0.13 |
| Peptic Ulcer Disease | 26 (2.4) | 18 (1.6) | 0.05 | 26 (2.4) | 224 (1.2) | 0.08 |
| Rheumatic Disease | 60 (5.5) | 57 (5.2) | 0.01 | 60 (5.5) | 466 (2.5) | 0.13 |
| Malignancy, skin cancers and lymphoproliferative disorders | 84 (7.7) | 72 (6.6) | 0.04 | 84 (7.6) | 645 (3.5) | 0.16 |
| Metastatic Solid Tumor | 25 (2.3) | 25 (2.3) | 0.00 | 25 (2.3) | 148 (0.8) | 0.10 |
| HIV/AIDS/Opportunistic Infections | 120 (11.0) | 94 (8.6) | 0.08 | 123 (11.2) | 1,425 (7.6) | 0.11 |
| Solid Organ Transplant | 53 (4.9) | 31 (2.8) | 0.09 | 56 (5.1) | 150 (0.8) | 0.20 |
Data are presented as mean [SD] for continuous measures, and n (%) for categorical measures.
Abbreviations: MAb = monoclonal antibody; SMD = standardized mean difference; IQR = interquartile range; BMI = body mass index; CKD = chronic kidney disease; ESRD = end-stage renal disease; HIV = Human Immunodeficiency Virus; AIDS = acquired immunodeficiency syndrome.